Ann and Sol Schreiber Mentored Investigator Award

2020 Grant Recipients

• David Chapel, MD, Brigham and Women’s Hospital
  The Migratory Precursor and Serous Carcinogenesis
• Yilun Deng, PhD, University of Texas Health Science Center at San Antonio
  CD122-Selective IL-2 Complexes as Novel Ovarian Cancer Therapy
• Elizabeth Lee, MD, Dana Farber Cancer Institute
  Phase II Trial of Gemcitabine+ATR Inhibitor: Translational Studies
• Jianhuang Lin, PhD, The Wistar Institute
  Targeting ER Stress Pathway in CARM1-Expressing Ovarian Cancer
• Duygu Ozmadenci, PhD, University of California - San Diego
  Sensitizing Ovarian Cancer to Immunotherapies
• Elizabeth Raupach, PhD, The Translational Genomics Research Institute
  Oncogenic Consequences of Altered SWI/SNF-RNA Interactions in SCCOHT
• Camilla Salvagno, PhD, Weill Medical College of Cornell University
  Dissecting How ER Stress Responses Shape Ovarian Cancer Immuno-Environments
• Janice Santiago, PhD, MD Anderson Cancer Center
  Crizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian Cancer
• Ignacio Vázquez-García, PhD, Memorial Sloan Kettering Cancer Center
  Co-Evolution and Dynamics of Malignant and Immune Cells in Ovarian Cancer
• Morozov Yaroslav, PhD, University of Pennsylvania
  The BRCA1-A as a Determinant of Chemotherapy Response in ATM Mutated Cells

2019 Grant Recipients

• Kristin G. Anderson, PhD, Fred Hutchinson Cancer Research Center
  Engineering Adoptive T Cell Therapy for Efficacy in Ovarian Cancer
• Alexander Cole, PhD, Magee-Womens Research Institute
  Investigating Regulators of Quiescence in Epithelial Ovarian Cancer
• Sarah Gitto, PhD, University of Pennsylvania
  Modeling Autologous TIL Therapy in Novel PARP Resistant PDX Model for Ovarian Cancer
• Guy Katz, MD, PhD, MD Anderson Cancer Center
  Therapeutic miRNA Targeting for Ovarian Cancer
• Isaac Klein, MD, PhD, Dana Farber Cancer Institute
  Transcriptional Regulatory Landscape of High Grade Serous Ovarian Cancer
• John Krais, PhD, Fox Chase Cancer Center
  Examining the Role of RNF168 in BRCA1 Mutant Ovarian Cancer
• Marilyne Labrie, PhD, Oregon Health and Science University
  Synergistic Lethality of PARP and P13K Pathway Inhibitors in Ovarian Cancer
• Jing Li, MD, PhD, University of Michigan
  ARID1A Drives Ovarian Cancer Immunotherapy
• Shariska Petersen, MD, University of Kansas Medical Center Research Institute
  Cyclin E and BRD4 as Markers for a New PARPi Drug Combination
• Alba Rodriguez-Garcia, PhD, University of Pennsylvania
  Targeting MISIIR with CAR T Cells for the Treatment of Ovarian Cancer
• Elaine Stur, PhD, MD Anderson Cancer Center
  Re-activating Anti-tumor Immunity Targeting PSEN1 in CAFS in Ovarian Cancer
• Shuai Wu, PhD, The Wistar Institute
  Synthetic Lethality for ARID1A Mutation in Ovarian Cancer
• Haineng Xu, PhD, University of Pennsylvania
  A Novel Targeted Therapy for Cyclin E Over Expressing Ovarian Cancers
• Zvi Yaari, PhD, Memorial Sloan Kettering Cancer Center
  Implantable Nanosensor for Early-Stage Detection of Ovarian Cancer

2018 Grant Recipients

• Damayanti Chakraborty, PhD, Massachusetts General Hospital
  Understanding Epigenetic Regulation of Copy Number Gains in Ovarian Cancer
• Daniele Chaves-Moreira, PhD, The University of Pennsylvania
  Isolation and Characterization of the PAX8 Transcriptional Complex
• Chin-Chi Chen, PhD, Johns Hopkins University
  Determining the Role of ARID1A in 53BP1-mediated DNA Damage Repair
• Shih-Hsun Chen, PhD, Beckman Research Institute of the City of Hope
  Targeting de-poly (ADP-ribosyl)ation for Ovarian Cancer Therapy
• Matthew Dean, PhD, The University of Illinois at Chicago
  The Ovarian Microenvironment in Metastasis of Fallopian Tube Derived Cancer
• Marcela Haro, PhD, Cedars-Sinai Medical Center
  Cancer Associated Fibroblasts Hinder the B Cell Anti-Tumor Response
• Ye Hu, MD, PhD, Cedars-Sinai Medical Center
  Reciprocal Roles of CAFs and CD4+ T Cells in Cancer Progression
• Justyna Kanska, PhD, Cedars-Sinai Medical Center
  Identifying Synthetic Lethal Targets to Mutant p53 in Development of HGSOC
• Goldie Lui, PhD, Fred Hutchinson Cancer Research Center
  Identifying Novel Targeted Therapies for MYC-driven Ovarian Cancer
• Sarah Stuckelberger, MD, The University of Pennsylvania
  Development of A Novel Syngeneic Model System for Ovarian Cancer Research
• Yinu Wang, PhD, Northwestern University
  Characterization of Chromatin Nanoarchitecture of Ovarian Cancer Stem Cells
• Shuang Zhang, PhD, New York University School of Medicine
  Modeling Human HGSOC Using Fallopian Tube Organoid Cultures

2017 Grant Recipients

• Nabanita Chatterjee, PhD, MD Anderson Cancer Center
  Ovarian Cancer Disrupts Circadian Cortisol Rhythms
• Marion Curtis, PhD, University of Chicago
  Mediators of Chemosensitivity and Immunotherapy Targets
• Anniina Farkkila, MD, PhD, Dana Farber Cancer Institute
  Overcoming PARP Inhibitor Resistance in Ovarian Cancer
• Jagmohan Hooda, PhD, University of Pennsylvania
  Loss of H2Bub1 Rewires Glutamine Metabolism During Progression of HGSOC
• Gilbert Huang, PhD, MD Anderson Cancer Center
  Targeting Dormant Ovarian Cancer Cells with Peptide Inhibitors of Autophagy
• Dongyu Jia, PhD, Cedars-Sinai Medical Center
  COL11A Is A Highly Specific Therapeutic Target in Cancer-Activated Stroma
• Venkatesh Krishnan, PhD, Stanford University
  Omental Macrophages: Drivers of Ovarian Cancer Metastasis
• Xianzhi Lin, PhD, Cedars-Sinai Medical Center
  Systematic Discovery of LncRNA Interactome in Epithelial Ovarian Cancer
• Beatrice Rondinelli, PhD, Dana Farber Cancer Institute
  EZH2 Determines PARPi Resistance and Fork Stabilization in Ovarian Tumors
• Priyanka Verma, PhD, University of Pennsylvania
  BRCA-Independent DNA Repair Pathways in Ovarian Cancer

2016 Grant Recipients

• Jessica Chacon, PhD, University of Pennsylvania
  Investigating the Role of Immunosuppressive Molecules in Ovarian Cancer
• Song Yi Ko, PhD, MD Anderson Cancer Center
  A “Trojan Horse” Mechanism That Mediates Resistance to Anti-VEGF Therapy
• Jill Madden, PhD, Inc., University of Kansas Medical Center Research Institute
  The Effect of FoxM1 Inhibition on Ovarian Cancer Immunity and Sensitivity
• Abir Mukherjee, PhD, University of Chicago
  Microenvironment Mediated Stabilization of Hif-1 Alpha in Ovarian Cancer
• Debarshi Roy, PhD, Mayo Clinic
  Crosstalk Between Glycolytic Pathway Inhibition and Increased Autophagy
• Qian Tan, MD, PhD, Stanford University
  Activation of Macrophages by Inhibiting CD47 Signaling in Ovarian Cancers
• Ryan Williams, PhD, Memorial Sloan Kettering Cancer Center
  An Ovarian Cancer Biosensor for Rapid, Non-invasive Disease Detection
• Nur Yucer, PhD, Cedars-Sinai Medical Center
  Modeling Mullarian HGSC Using BRCA1 Patient Derived iPSCs
• Fan Zhao, PhD, Stanford University
  Ovarian Cancer Antigen Discovery by Single t-cell Analysis and pHLA Library
• Hengrui Zhu, PhD, The Wistar Institute
  Epigenetic Targeting of Cancer Stem-like Cells (CSCs) in Ovarian Cancer

2015 Grant Recipients

• Juan Cubillos-Ruiz, PhD, Weill Medical College of Cornell University
  ER Stress Sensor XBP1 as a Key Regulator of Ovarian Cancer Immunity
• Justyna Filant, PhD, MD Anderson Cancer Center
  Novel Extra Cellular RNA-based Combinatorial RNA Inhibition Therapy
• Xiaowen Hu, PhD, University of Pennsylvania
  Long Non-coding RNAs in Epithelia Ovarian Cancer
• Petar Jelinic, PhD, Memorial Sloan Kettering Cancer Center
  EMSY Suppresses HDR in a BRCA2-interaction-independent Manner
• Zeina Kais, PhD, Dana Farber Cancer Institute
  Synthetic Lethality Between CCNE1 Amplification and USP1 Inhibition
• Bob McGray, PhD, Roswell Park Cancer Institute
  Combination Oncolytic Virotherapy/ACT for Ovarian Cancer Treatment
• Alfredo Perales-Puchalt, MD, The Wistar Institute
  Targeting FSH Receptor with Chimeric Antigen Receptor in Ovarian Cancer
• Nicole Spardy, PhD, Dana Farber Cancer Institute
  Identification of New Genetic Dependencies in HR-deficient Ovarian Cancers
• Wei Wei, PhD, Massachusetts General Hospital
  Genomic Analysis to Predict Recurrence in Early Stage Ovarian Cancer
• Oladapo Yeku, MD, PhD, Memorial Sloan Kettering Cancer Center
  A Phase I Trial Using Chimeric Antigen Receptors in Ovarian Cancer Patients

2014 Grant Recipients

• Nima Aghaeepour, PhD, Stanford University
  Computationally-guided Characterization of Therapy-resistant Ovarian Tumors
• Raphael Ceccaldi, PharmD, PhD, Dana Farber Cancer Institute
  A Bioinformatic Screen Identifies POLQ Overexpression in Ovarian Cancers
• Ilana Chefetz, PhD, University of Michigan
  A Role for ALDH in the Regulation of Necroptosis in Ovarian Cancer Area of research: Therapeutic Targeting
• Ellen Cheon, PhD, Cedars-Sinai Medical Center
  Collagen-Remodeling Genes Provide a Niche for Ovarian Cancer
• Laura Dillon, PhD, University of Virginia
  Differential MicroDNA Generation in Ovarian Cancer
• Mo Li, PhD, University of Michigan
  Mechanism of PARP Inhibitor in Ovarian Cancer Therapy Cancer
• Kyung Hee Noh, PhD, MD Anderson Cancer Center
  Targeting Adaptive Changes to anti-VEGF Therapy in Ovarian Cancer
• Shailja Pathania, PhD, Dana Farber Cancer Institute
  Novel Therapeutic Targets for High-Grade Serous Ovarian Carcinoma
• Megan Rice, ScD, Brigham and Women’s Hospital
  Dietary Fat, Cholesterol, and Ovarian Cancer Risk
• Yang Yang, PhD, Yale University
  P53 Aggregation: a New Target to Combat Ovarian Cancer Platinum-Resistance
• Chi Lam Au Yeung, PhD, MD Anderson Cancer Center
  Adipose Tissue Derived Exosomal miRNAs in Ovarian Cancer Progression
• Yuyu Yuyu, PhD, Johns Hopkins University School of Medicine
  Targeting Spleen Tyrosine Kinase in Chemoresistant Ovarian Cancer

2013 Grant Recipients

• Pradeep Chaluvally-Raghavan, PhD, MD Anderson Cancer Center
  Role of microRNAs in the 3q26 Amplicon in Ovarian Cancer Pathophysiology and Therapy
• Ronald Chandler, PhD, University of North Carolina - Chapel Hill
  A Genetically Relevant Mutant Mouse Model of Epithelial Ovarian Cancer
• Diana Hargreaves, PhD, Stanford University
  Targeting Ovarian Cancer via Cooperative Oncogene Interactions
• Christine Lawson, PhD, University of California - San Diego
  Testing the FAK and Talin Signaling Linkage in Ovarian Tumor Cell Metastasis
• Teng Ma, MD, PhD, University of Michigan - Ann Arbor
  The Analysis of NEDD8-activating Enzyme Inhibitor MLN4924 on Ovarian Cancer
• David Pepin, PhD, Massachusetts General Hospital
  Mechanisms and Markers to Target a Stem Enriched Population of Primary Ovarian Cancer Ascites with the Müllerian Inhibiting Substance
• Yin Wang, PhD, Mayo Clinic Jacksonville
  Protein Kinase C iota is a Novel Therapeutic Target for Ovarian Cancer Treatment

2012 Grant Recipients

• Bin Guan, PhD, Johns Hopkins University School of Medicine
  Functional Characterization of the Tumor Suppressor ARID1A in Ovarian Cancer
• Kate Lawrenson, PhD, University of Southern California
  Modeling Stem Cell Origins of Epithelial Ovarian Carcinomas
• Hanqing Liu, PhD, Fox Chase Cancer Center
  Targeting Signaling Networks via RNAi to Improve Therapy for Ovarian Cancer
• Ngai Na Co, PhD, MD Anderson Cancer Center
  The Role of Stromal microRNA 21 in Omental Ovarian Cancer Progression
• See-Hyoung Park, PhD, Stanford University
  Targeting Ovarian Cancer with Combination of Olaparib and Bepridil
• Melinda Yates, PhD, MD Anderson Cancer Center
  Unraveling the Initiation of Ovarian Cancer: The BRCA1-Heterozygous Mouse as a Model System

2011 Grant Recipients

• Anirban Mitra, PhD, University of Chicago
  How Do Cells Near Ovarian Cancer Cells Play a Role in the Disease?
• Gregory Motz, PhD, University of Pennsylvania
  Stimulating Immune Cells to Fight Ovarian Cancer
• Ruth Perets, MD, PhD, Dana Farber Cancer Institute
  Trying to Identify the Cell Responsible for Ovarian Cancer
• Sharmistha Sarkar, PhD, MD Anderson Cancer Center
  Finding a Marker to Detect Early Stage Ovarian Cancer
• Sherry Wu, PhD, MD Anderson Cancer Center
  Novel Approach to Destroy the Blood Supply that Feeds Ovarian Cancer Tumors
• Tsz-Lun Yeung, PhD, MD Anderson Cancer Center
  Understanding How Ovarian Cancer Spreads

2008 Grant Recipients

• Weiwei Shan, PhD, MD Anderson Cancer Center
  Cellular Microenvironment Role in Ovarian Cancer Development
• Takayo Ota, MD, PhD, Mayo Clinic Rochester
  Characterizing the Genetic Alterations of Aggressive Ovarian Cancer
• Xiaoping He, MD, PhD, Mayo Clinic Rochester
  Understanding the Molecular Pathways to Chemotherapy Resistance in Ovarian Cancer
• Thuy-Vy Do, PhD, Fox Chase Cancer Center
  Understanding How Ovarian Cancer Spreads
• Lejla Delic, MD, Cedars-Sinai Medical Center
  A New Class of Drugs with Potential Against Ovarian Cancer: PARP-inhibitors

2007 Grant Recipients

• Hong Zhang, PhD, Fox Chase Cancer Center
  Novel Animal Model to Test Drugs Against Ovarian Cancer
• Melissa Merritt, PhD, Brigham and Women’s Hospital
  How Might Different Tissues in the Ovary Act on Each Other to Induce Cancer
• Mitchell Cheung, PhD, Fox Chase Cancer Center
  Testing New Therapeutic Agents to Treat Ovarian Cancer
• Kuang-Hung Cheng, PhD, Brigham and Women’s Hospital
  Animal Model to Study Ovarian Cancer Stem Cells

2006 Grant Recipients

• Ramandeep Rattan, PhD, Mayo Clinic
  Gene May Be an Early Marker for Ovarian Cancer
• Andres Matoso, MD, Cornell University
  An Animal Model to Study Major Genetic Alterations in Ovarian Cancer
• Aliza Leiser, MD, Yale University
  Clinical Implications of the TLR-4MYD88 Pathway in EOC
• Audrey Gagnon, PhD, Brigham and Women’s Hospital
  New Analytical Tool for Ovarian Cancer Detection
• Adam Clauss, PhD, Dana Farber Cancer Institute
  Does Ovarian Cancer Originate in the Fallopian Tube?
• Maria Barbolina, PhD, University of Illinois - Chicago
  Epigenetic Regulation of Metastasis-Associated Gene Expression in EOC
• Tsukasa Baba, Duke University
  Using Public Resources to Find New Drugs to Treat Resistant Ovarian Cancer

2005 Grant Recipients

• Deyin Xing, MD, PhD, Massachusetts General Hospital
  Models to Study Hereditary Ovarian Cancer
• Jason Wilken, PhD, Yale University
  Making an Antibody Treatment for Breast Cancer Work for Ovarian Cancer
• Ritu Salani, MD, Johns Hopkins University School of Medicine
  DNA Fragments Might be a Way to Screen for Ovarian Cancer
• Joseph Kwong, PhD, Brigham and Women’s Hospital
  Could Inflammation of Ovarian Cells be the Cause of Ovarian Cancer?
• Amy BonDurant, MD, Duke University
  Chemical Changes on DNA May Be a Way to Screen for Ovarian Cancer and its Recurrence
• Donna Badgewell, PhD, MD Anderson Cancer Center
  Developing a Screening Test for Ovarian Cancer

2004 Grant Recipients

• Xiaoyan Ni, PhD, Brigham and Women’s Hospital
  Biomarkers for Ovarian Cancer
• Brian Barnett, MD, Tulane University Health Sciences Center
  Depleting Regulatory T Cells to Treat Ovarian Cancer

2003 Grant Recipients

• Monique Spillman, MD, PhD, Duke University Medical Center
  Role of MAP2K4 Suppressing Metastasis of Serous Ovarian Cancers
• Naomi Hunder, MD, Fred Hutchinson Cancer Research Center
  Evaluation of Mesothelin as a Taret Antigen in Ovarian Cancer
• Kuan-Chun Huang, PhD, Brigham and Women’s Hospital
  A Possible New Marker for Drug Resistance of Ovarian Cancer
• Jeremy Chien, PhD, Mayo Clinic
  How Cell Shape Changes Lead to Metastasis in Ovarian Cancer